Statin Use and the Incidence of Advanced Age-related Macular Degeneration in the Complications of Age-related Macular Degeneration Prevention Trial

Ophthalmology

Volumn 116, Issue 12, 2009, Pages 2381-2385

  Maguire, Maureen G ^a   Ying, Gui shuang ^a   McCannel, Colin A ^b   Liu, Chengcheng ^a   Dai, Yang ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; DRUG USE; DRUSEN; FEMALE; GEOGRAPHIC RETINA ATROPHY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; COHORT STUDIES; CORONARY DISEASE; DRUG UTILIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; GEOGRAPHIC ATROPHY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; ODDS RATIO; VISUAL ACUITY;

EID: 70649100017     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.06.055     Document Type: Article

References (33)

1. Hall N.F., Gale C.R., Syddall H., et al. Risk of macular degeneration in users of statins: cross sectional study. BMJ 323 (2001) 375-376
2. Guymer R.H., Chiu A.W., Lim L., and Baird P.N. HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration?. Surv Ophthalmol 50 (2005) 194-206
3. Delcourt C., Michel F., Colvez A., et al., POLA Study Group. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol 8 (2001) 237-249
4. Klein R., Klein B.E., Tomany S.C., et al. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 121 (2003) 1151-1155
5. McCarty C.A., Mukesh B.N., Guymer R.H., et al. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression [letter]. Med J Aust 175 (2001) 340
6. McCarty C.A., Mukesh B.N., Fu C.L., et al. Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol 119 (2001) 1455-1462
7. McGwin Jr. G., Owsley C., Curcio C.A., and Crain R.J. The association between statin use and age related maculopathy. Br J Ophthalmol 87 (2003) 1121-1125
8. McGwin Jr. G., Xie A., and Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology 112 (2005) 488-494
9. McGwin Jr. G., Modjarrad K., Hall T.A., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. Arch Ophthalmol 124 (2006) 33-37
10. Smeeth L., Cook C., Chakravarty U., et al. A case control study of age related macular degeneration and use of statins. Br J Ophthalmol 89 (2005) 1171-1175
11. Wilson H.L., Schwartz D.M., Bhatt H.R., et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 137 (2004) 615-624
12. van Leeuwen R., Tomany S.C., Wang J.J., et al. Is medication use associated with the incidence of early age-related maculopathy?. Pooled findings from 3 continents. Ophthalmology 111 (2004) 1169-1175
13. Chuo J.Y., Wiens M., Etminan M., and Maberley D.A. Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies. Ophthalmic Epidemiol 14 (2007) 367-374
14. Klein R., Deng Y., Klein B.E., et al. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol 143 (2007) 473-483
15. Klein R., Knudtson M.D., and Klein B.E. Statin use and the five-year incidence and progression of age-related macular degeneration. Am J Ophthalmol 144 (2007) 1-6
16. Tan J.S., Mitchell P., Rochtchina E., and Wang J.J. Statins and the long term risk of incident age-related macular degeneration: the Blue Mountains Eye Study. Am J Ophthalmol 143 (2007) 685-687
17. Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the Complications of Age-related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 113 (2006) 1974-1986
18. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials 1 (2004) 91-107
19. Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 111 (2004) 1307-1316
20. Klein R., Davis M.D., Magli Y.L., et al. The Wisconsin Age-Related Maculopathy Grading System. Ophthalmology 98 (1991) 1128-1134
21. Bird A.C., Bressler N.M., Bressler S.B., et al., International ARM Epidemiological Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 39 (1995) 367-374
22. Wei L.J., Lin D.Y., and Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 84 (1989) 1065-1073
23. Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the Complications of Age-Related Macular Degeneration Prevention Trial. Ophthalmology 115 (2008) 1474-1479
24. Hageman G.S., Luthert P.J., Victor Chong N.H., et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20 (2001) 705-732
25. Despriet D.D., Klaver C.C., Witteman J.C., et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 296 (2006) 301-309
26. Seddon J.M., Gensler G., Milton R.C., et al. Association between C-reactive protein and age-related macular degeneration. JAMA 291 (2004) 704-710
27. Seddon J.M., George S., Rosner B., and Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 123 (2005) 774-782
28. Ridker P.M., Rifai N., Pfeffer M.A., et al., Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (1999) 230-235
29. Ridker P.M., Rifai N., and Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001) 1191-1193
30. McGwin Jr. G., and Owsley C. Statins and age-related macular degeneration [letter]. Am J Ophthalmol 138 (2004) 688 author reply 688-9
31. Wong T.Y., and Rogers S.L. Statins and age-related macular degeneration: time for a randomized controlled trial?. Am J Ophthalmol 144 (2007) 117-119
32. Miller G.E., and Stagnitti M.N. Statin use in the civilian noninstitutionalized Medicare population in 2002. Statistical Brief #96. September 2005. http://www.meps.ahrq.gov/mepsweb/data_files/publications/st96/stat96.pdf Accessed May 20, 2009
33. Stagnitti M.N. Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. Statistical Brief #205. May 2008. http://www.meps.ahrq.gov/mepsweb/data_files/publications/st205/stat205.pdf Accessed May 20, 2009